119 related articles for article (PubMed ID: 23098574)
1. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.
Montagna E; Maisonneuve P; Rotmensz N; Cancello G; Iorfida M; Balduzzi A; Galimberti V; Veronesi P; Luini A; Pruneri G; Bottiglieri L; Mastropasqua MG; Goldhirsch A; Viale G; Colleoni M
Clin Breast Cancer; 2013 Feb; 13(1):31-9. PubMed ID: 23098574
[TBL] [Abstract][Full Text] [Related]
2. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
3. Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Morgan E; Suresh A; Ganju A; Stover DG; Wesolowski R; Sardesai S; Noonan A; Reinbolt R; VanDeusen J; Williams N; Cherian MA; Li Z; Young G; Palettas M; Stephens J; Liu J; Luff A; Ramaswamy B; Lustberg M
World J Surg Oncol; 2020 Jan; 18(1):11. PubMed ID: 31937323
[TBL] [Abstract][Full Text] [Related]
4. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis.
Sanges F; Floris M; Cossu-Rocca P; Muroni MR; Pira G; Urru SAM; Barrocu R; Gallus S; Bosetti C; D'Incalci M; Manca A; Uras MG; Medda R; Sollai E; Murgia A; Palmas D; Atzori F; Zinellu A; Cambosu F; Moi T; Ghiani M; Marras V; Santona MC; Canu L; Valle E; Sarobba MG; Onnis D; Asunis A; Cossu S; Orrù S; De Miglio MR
BMC Cancer; 2020 Jun; 20(1):491. PubMed ID: 32487046
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hormonal receptor and HER-2 status between breast primary tumours and relapsing tumours: clinical implications of progesterone receptor loss.
Bogina G; Bortesi L; Marconi M; Venturini M; Lunardi G; Coati F; Massocco A; Manfrin E; Pegoraro C; Zamboni G
Virchows Arch; 2011 Jul; 459(1):1-10. PubMed ID: 21643691
[TBL] [Abstract][Full Text] [Related]
6. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.
Abbott DE; Brouquet A; Mittendorf EA; Andreou A; Meric-Bernstam F; Valero V; Green MC; Kuerer HM; Curley SA; Abdalla EK; Hunt KK; Vauthey JN
Surgery; 2012 May; 151(5):710-6. PubMed ID: 22285778
[TBL] [Abstract][Full Text] [Related]
7. Effects of hormone receptor status on patient clinic and survival in HER2 positive breast cancer.
Yılmaz M; Erdiş E; Uçar M; Demir N; Alandağ C; Yücel B
Jpn J Clin Oncol; 2024 May; 54(5):521-529. PubMed ID: 38336481
[TBL] [Abstract][Full Text] [Related]
8. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
9. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.
Huober J; Gelber S; Goldhirsch A; Coates AS; Viale G; Öhlschlegel C; Price KN; Gelber RD; Regan MM; Thürlimann B
Ann Oncol; 2012 Nov; 23(11):2843-2851. PubMed ID: 22707751
[TBL] [Abstract][Full Text] [Related]
10. Triple-negative apocrine carcinoma: A rare pathologic subtype with a better prognosis than other triple-negative breast cancers.
Arciero CA; Diehl AH; Liu Y; Sun Q; Gillespie T; Li X; Subhedar P
J Surg Oncol; 2020 Nov; 122(6):1232-1239. PubMed ID: 32668059
[TBL] [Abstract][Full Text] [Related]
11. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype.
McCart Reed AE; Kalinowski L; Simpson PT; Lakhani SR
Breast Cancer Res; 2021 Jan; 23(1):6. PubMed ID: 33413533
[TBL] [Abstract][Full Text] [Related]
12. Metaplastic breast cancers and triple-negative breast cancers of no special type: are they prognostically different? A systematic review and meta-analysis.
Corso G; D'Ecclesiis O; Magnoni F; Mazzotta E; Conforti F; Veronesi P; Sajjadi E; Venetis K; Fusco N; Gandini S
Eur J Cancer Prev; 2022 Sep; 31(5):459-466. PubMed ID: 35088973
[TBL] [Abstract][Full Text] [Related]
13. Breast Cancer Histopathology in the Age of Molecular Oncology.
Kos Z; Nielsen TO; Laenkholm AV
Cold Spring Harb Perspect Med; 2024 Jun; 14(6):. PubMed ID: 38151327
[TBL] [Abstract][Full Text] [Related]
14. Commentary: Outcomes of Metaplastic Breast Cancer vs. Triple-Negative Breast Cancer.
Agarwal G; Chanthar KMMV
World J Surg; 2023 Dec; 47(12):3203-3204. PubMed ID: 37777669
[No Abstract] [Full Text] [Related]
15. Rare Breast Cancer Histotypes-A Retrospective Study and Literature Review.
Lam AHK; Co MTH; Kwong A
J Clin Med; 2024 Jan; 13(3):. PubMed ID: 38337337
[TBL] [Abstract][Full Text] [Related]
16. The Clinicopathological Features and Survival Outcomes of Different Histological Subtypes in Triple-negative Breast Cancer.
Liao HY; Zhang WW; Sun JY; Li FY; He ZY; Wu SG
J Cancer; 2018; 9(2):296-303. PubMed ID: 29344276
[No Abstract] [Full Text] [Related]
17. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Bianchini G; Balko JM; Mayer IA; Sanders ME; Gianni L
Nat Rev Clin Oncol; 2016 Nov; 13(11):674-690. PubMed ID: 27184417
[TBL] [Abstract][Full Text] [Related]
18. Novel prognostic markers for patients with triple-negative breast cancer.
Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemically defined subtypes and outcome of apocrine breast cancer.
Dellapasqua S; Maisonneuve P; Viale G; Pruneri G; Mazzarol G; Ghisini R; Mazza M; Iorfida M; Rotmensz N; Veronesi P; Luini A; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2013 Apr; 13(2):95-102. PubMed ID: 23245877
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype.
McGhan LJ; McCullough AE; Protheroe CA; Dueck AC; Lee JJ; Nunez-Nateras R; Castle EP; Gray RJ; Wasif N; Goetz MP; Hawse JR; Henry TJ; Barrett MT; Cunliffe HE; Pockaj BA
Ann Surg Oncol; 2014 Feb; 21(2):361-7. PubMed ID: 24046116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
